-
While new methods are gaining favor with women, oral contraceptives (OCs) continue to be a popular method of birth control, say respondents to the 2008 Contraceptive Technology Update Contraception Survey. About 42% of survey participants report over half of their patients leave the office with an OC prescription in hand.
-
Where do generic oral contraceptives fit in your facility's formulary? About 70% of participants in the 2008 Contraceptive Technology Update Contraception Survey say their facilities have increased the use of generic oral contraceptives due to budget constraints, up 5% from 2007's statistic.
-
When it comes to choosing an effective contraceptive, many women look to the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera Pfizer; New York City, Medroxyprogesterone Acetate Injection, Teva Pharmaceuticals USA; North Wales, PA), say respondents to the 2008 Contraceptive Technology Update Contraception Survey.
-
-
Soft-tissue rheumatism often is a challenging disorder for the primary care physicians. The patient's symptoms often are vague, and the physical examination and laboratory testing often do not give comforting confirmatory findings. This issue reviews common conditions that afflict many of our patients and that, although often not serious, cause significant distress and morbidity. With the proper history and attention to presenting features, effective and professionally rewarding treatments are available.
-
5-α reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
-
-
-
Among almost 6000 patients with COPD who were using other classes of respiratory therapies, the addition of tiotropium, compared with placebo, was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period, but did not result in benefits in the rate of decline in FEV1.
-
The FDA has extended the approval for the Human Papillomavirus Quadrivalent Recombinant Vaccine to include the prevention of vaginal and vulvar cancer. The vaccine, originally approved in 2006, is already approved for the prevention of cervical cancer and genital warts.
